公开(公告)号：US20160168142A1

公开(公告)日：2016-06-16

申请号：US14906974

申请日：2014-07-22

Applicant: BASF SE

Inventor： Andreas HAFNER ,  Fritz BLATTER ,  Martin SZELAGIEWICZ ,  Bernd SIEBENHAAR ,  Tiziana CHIODO ,  Tobias HINTERMANN ,  Beate SALVADOR ,  Marcus VOSSER

IPC: C07D417/12 ,  C07C55/12 ,  C07D213/80 ,  C07D275/06

CPC classification number: C07D417/12 ,  C07C55/12 ,  C07D213/80 ,  C07D275/06

Abstract: The present invention primarily relates to salts of Dasatinib, wherein the salts are in amorphous form. The salts described herein preferably comprise a cation of a compound of formula 1 and an anion of a second compound selected from the group consisting of glutaric acid, nicotinic acid and saccharin. The invention is further related to pharmaceutical compositions comprising such a salt. Furthermore, the invention relates to processes for preparing said salts. The invention also relates to several aspects of using said salt or pharmaceutical composition to treat a disease.

Abstract translation: 本发明主要涉及达沙替尼的盐，其中盐是无定形的。 本文所述的盐优选包含式1的化合物的阳离子和选自戊二酸，烟酸和糖精的第二化合物的阴离子。 本发明还涉及包含这种盐的药物组合物。 此外，本发明涉及制备所述盐的方法。 本发明还涉及使用所述盐或药物组合物治疗疾病的若干方面。